Grown Rogue Reports Fourth Quarter and Full Year 2025 Results & Provides Outlook
Financial Statements Converted to
Highlights:
- Revenue of
$32.4 million for the full year 2025, up 22% from$26.6 million in 2024, with growth driven by the late-2024 entry into theNew Jersey market, partly offset by the termination of the Vireo consulting agreement in September of 2024 and substantial pricing pressure that contributed to revenue declines of 22% inMichigan and 8% inOregon . - Adjusted EBITDA (non-GAAP) of
$5.4 million (16.5% margin) for 2025, up 42% from$3.8 million in 2024, with contributions fromNew Jersey partly offset by pricing pressure inMichigan andOregon and higher corporate overhead associated with growth initiatives. - GAAP net income of
$3.2 million for 2025, including a non-cash gain of approximately$5.9 million related to the fair value of derivative liabilities. - Revenue of
$8.8 million for Q4 2025, Adjusted EBITDA (non-GAAP) of$1.2 million (13.4% margin), and GAAP net income (loss) of($2.1) million for the quarter. All financial information in this release, including full-year 2025 results and the tables below, is presented on a preliminary, unaudited basis and reflects the Company's transition from IFRS to GAAP. -
New Jersey : the Company's affiliate, ABCO Garden State ("ABCO") ended its first year of operations with full sell-through of packaged, branded products. The ABCO Phase II expansion project is underway, with an additional flower room already planted that is expected to add approximately 25% to capacity, with first harvest expected in May. Management currently expects to complete the remaining three flower rooms incrementally every two to three months through the remainder of 2026, bringing total capacity to approximately 16,000 square feet of flowering canopy. -
Oregon andMichigan : both markets experienced significant pricing headwinds in 2025. For the full year, the Company's overall production cost of dry-weight cannabis biomass in its mature facilities remained below$225 per pound, with continuous improvements in standard operating procedures (SOPs) and modest infrastructure investments contributing to cost efficiency. -
Minnesota : the Company commenced construction work for its new-build cultivation facility inFridley . Phase I, consisting of approximately 8,000 square feet of flowering canopy, is currently anticipated to come online late in the third quarter of 2026, with revenue expected in the first quarter of 2027. -
Illinois : subsequent to year end, the Company announced definitive agreements to accelerate entry into theIllinois market through a turnkey cultivation facility inDwight, Illinois . - Closed two tranches under the Company's senior secured credit facility in 2025, totaling
$12.0 million in aggregate principal, with a blended interest rate of 7.84%. - Management is introducing a multi-year growth framework, including long-term (3-5 year) objectives and annual financial guidance.
Preliminary Q1 2026 update: With the first quarter complete at the time of this release, management anticipates revenue growth of greater than 20% in Q1 2026 compared to Q1 2025, driven primarily by
Fourth Quarter 2025 update: Fourth quarter 2025 results reflected continued momentum in
All financial information for 2025, including Q4 2025 and the tables below, is presented on a preliminary, unaudited basis. The Company expects to file its Annual Report on Form 10-K, including audited financial statements for the year ended
Management Commentary
"2025 was focused on growth and investment for the future with our commitments in new markets and additions to our team, while staying grounded in what we do best: consistently delivering craft-quality flower, supported by a cost structure designed to compete through price normalization.
In
In addition to maintaining our relentless focus on the efficient production of craft-quality flower, our main priorities in 2026 are to activate our new project in
We have made significant efforts to prepare for this growth, most notably through key additions to our team and the expansion of our product portfolio and marketing resources, largely in support of shifting more of our sales mix to branded, packaged product. With the change to GAAP reporting and our decision to provide guidance, including a multi-year growth framework, we believe investors will be better able to evaluate our performance against our plans. In addition, we're sticking with our commitment of transparency around the key operating metrics that support our execution, with some minor adjustments and enhancements to our externally reported key performance indicators ("KPIs") to better compare trends and results across markets," said
We also continue to pursue modest infrastructure improvements in our existing
We are introducing targets for profit growth and incremental returns to make our priorities more measurable, while maintaining flexibility to act on distressed opportunities that meet our underwriting criteria. Our objective is to drive capital-efficient profit growth, capitalizing on our core capabilities and what we believe is a rich opportunity set presented by the cannabis industry."
Operating KPIs by Market
|
|
Q4 2025 |
Q3 2025 |
Q2 2025 |
Q1 2025 |
Q4 2024 |
Q3 2024 |
Q2 2024 |
Q1 2024 |
|
|
|
|
|
|
|
|
|
|
|
Total Flower Harvested (lbs) |
2,980 |
3,547 |
3,392 |
3,423 |
3,239 |
3,100 |
2,457 |
2,799 |
|
Flower Cost Per Pound Produced |
$ 479 |
$ 374 |
$ 408 |
$ 379 |
$ 414 |
$ 425 |
$ 563 |
$ 463 |
|
Total Flower Yield (g/sf)1 |
68 |
73 |
72 |
69 |
69 |
63 |
58 |
57 |
|
"A" Flower Yield (g/sf)1 |
42 |
49 |
45 |
42 |
49 |
43 |
42 |
43 |
|
$ Bulk Flower ASP2 |
$ 466 |
$ 499 |
$ 511 |
$ 610 |
$ 691 |
$ 736 |
$ 768 |
$ 787 |
|
$ Packaged Flower ASP2 |
- |
- |
- |
- |
- |
- |
- |
- |
|
Portion of Revenue for Packaged Products |
9 % |
15 % |
13 % |
12 % |
12 % |
12 % |
9 % |
7 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Flower Harvested (lbs) |
3,960 |
3,518 |
3,391 |
2,948 |
3,104 |
3,215 |
3,010 |
2,757 |
|
Flower Cost Per Pound Produced |
$ 361 |
$ 364 |
$ 374 |
$ 434 |
$ 411 |
$ 407 |
$ 432 |
$ 486 |
|
Total Flower Yield (g/sf)1 |
82 |
77 |
71 |
64 |
66 |
65 |
64 |
61 |
|
"A" Flower Yield (g/sf)1 |
49 |
46 |
45 |
35 |
39 |
41 |
43 |
44 |
|
$ Bulk Flower ASP2 |
$ 692 |
$ 775 |
$ 734 |
$ 740 |
$ 833 |
$ 902 |
$ 1,013 |
$ 1,006 |
|
$ Packaged Flower ASP2 |
$ 957 |
$ 900 |
$ 972 |
$ 940 |
$ 984 |
$ 1,041 |
$ 1,209 |
$ 1,231 |
|
Portion of Revenue for Packaged Products |
24 % |
17 % |
17 % |
18 % |
27 % |
35 % |
36 % |
38 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Flower Harvested (lbs) |
1,678 |
1,306 |
1,546 |
1,518 |
|
|
|
|
|
Flower Cost Per Pound Produced |
$ 750 |
$ 884 |
$ 705 |
$ 658 |
|
|
|
|
|
Total Flower Yield (g/sf)1 |
64 |
59 |
58 |
57 |
|
|
|
|
|
"A" Flower Yield (g/sf)1 |
37 |
38 |
32 |
36 |
|
|
|
|
|
$ Bulk Flower ASP2 |
$ 1,193 |
$ 1,032 |
$ 939 |
$ 899 |
|
|
|
|
|
$ Packaged Flower ASP2 |
$ 2,131 |
$ 2,044 |
$ 2,562 |
$ 2,504 |
|
|
|
|
|
Portion of Revenue for Packaged Products |
95 % |
92 % |
93 % |
89 % |
|
|
|
|
|
*Includes only indoor operations
¹ g/sf = grams of product were harvested for every square foot of growing space |
|
|
|
|
|
|
||
Guidance and Long-Term (3-5 Year) Growth Objectives
Management is providing the following financial framework to assist investors in evaluating the Company's growth strategy and capital allocation discipline. The guidance and long-term objectives set out below reflect current expectations, assumptions and management objectives as of the date of this release and are subject to the forward-looking statements disclosure included herein.
Growth Framework:
- Selective new builds in undersupplied markets where craft-quality flower is expected to earn attractive wholesale economics and support the capital intensity of new-build projects.
- Fixer-upper takeovers and distressed opportunities where we believe disciplined execution can improve yield, consistency, and cost controls, typically with lower capital expenditure requirements.
- Focused product expansion intended to grow wallet share while maintaining a disciplined stock keeping unit (SKU) set and consistent quality standards.
- Underwriting discipline: management evaluates investments against mature-market, normalized pricing assumptions; early-cycle pricing upside is not required to meet return targets.
Long-term (3-5 year) Targets and Guidance
- Long-term (3-5 year) targets, using 2027 as the base year
- Revenue growth of 25% per year, compounded
- Profit growth (Adjusted EBITDA1) of 35% per year, compounded
- Return on
Incremental Invested Capital ("ROIIC")2 of greater than 75%
- 2026 Guidance (Revenue / Adjusted EBITDA1):
$32 -$35 million /$6 -$8 million . - 2027 Guidance (Revenue / Adjusted EBITDA1):
$50 -$58 million /$14 -$18 million .
|
1
Adjusted EBITDA (non-GAAP) excludes pre-revenue, startup expenses associated with new market expansion.
|
2026 Guidance Assumptions: 2026 guidance excludes the start-up (pre-revenue) expenses in both
2027 Guidance Assumptions: 2027 guidance assumes modest wholesale price normalization from 2026 levels in
General Assumptions. Guidance and long-term objectives exclude any potential changes in
State-by-State Indoor Cultivation Flowering Capacity (Bench Canopy)
|
State |
Canopy / capacity online (sq. ft.) |
Under development (sq. ft.) |
Nameplate capacity
|
Notes |
|
|
|
|
|
|
|
└ Airport |
9,152 |
N/A |
9,152 |
Approximately 30,000 sq. ft. indoor facility space. |
|
└ Rossanley |
5,600 |
N/A |
5,600 |
Eight dedicated flower rooms; nearly four harvests per month. |
|
|
14,550 |
N/A |
14,550 |
Facility currently operates approximately 50,000 sq. ft., including fourteen flowering rooms and related support space. |
|
|
8,000 |
8,000 |
16,000 |
Expansion underway through 2026, with total capacity anticipated to increase to approximately 16,000 sq. ft. of flowering canopy. |
|
|
N/A |
8,000 |
30,000 |
Phase I includes approximately 8,000 sq. ft. of flowering canopy with products expected to be available for sale in early 2027 |
|
|
N/A |
5,000 |
14,000 |
Approximately 66,000 sq. ft. leased facility, including 23,000 sq. ft. greenhouse, with existing indoor flower capacity of 5,000 sq. ft. targeted online in Q4 2026, expandable to 14,000 sq. ft. subject to regulatory approval |
|
Totals |
37,302 |
21,000 |
89,302 |
|
GAAP Reporting Conversion and Consolidation Update
We no longer qualify as a "foreign private issuer" as such term is defined in Rule 405 under the
In addition, as required pursuant to section 4.3(4) of National Instrument 51-102 - Continuous Disclosure Obligations, we must restate and file under our profile on SEDAR+ (www.sedarplus.com), our interim financial reports for the fiscal year ended
The adoption of GAAP and consolidation of ABCO affect the presentation and comparability of certain line items and non-GAAP measures, including items influenced by lease accounting and other classification differences. As a result, some reported measures (including Adjusted EBITDA (non-GAAP)) may not be directly comparable to prior periods. We will provide reconciliations and, where applicable, recast comparative information in our MD&A and financial schedules to assist investors in evaluating period-to-period performance.
Full Year 2025 vs. 2024 Summary (Preliminary, Unaudited)
(US $ in millions)
|
Metric |
2025 |
2024 |
YoY Δ |
|
Revenue* (GAAP) |
|
|
22 % |
|
GAAP Net Income (loss) ¹ |
|
( |
n.m. |
|
EBITDA 2 |
|
|
54 % |
|
Adjusted EBITDA 3 |
|
|
43 % |
|
% Adjusted EBITDA Margin 4 |
16.6 % |
14.1 % |
248bps |
|
Cash and Cash Equivalents 5 |
|
|
131 % |
|
n.m. = not meaningful. |
|
*See "GAAP Reporting Conversion and Consolidation Update" and notes below regarding comparability and |
|
¹ 2025 GAAP net income was positively impacted by gains related to changes in the fair value of derivative liabilities. Accordingly, GAAP net income should not be viewed in isolation as an indicator of operating performance. "EBITDA" and "Adjusted EBITDA" (each as hereinafter defined) are non-GAAP financial measures and are presented as supplemental measures to assist investors in evaluating underlying operating performance. |
|
² EBITDA is a non-GAAP financial measure. We define EBITDA as net income or loss for a period, as reported, before interest, taxes, depreciation and amortization, and as further adjusted to remove transaction costs, share-based compensation expense, accretion expense, gain (loss) on derecognition of derivative liabilities, as well as other non-cash items and items not representative of operational performance as reported in net income (loss).. |
|
3 Adjusted EBITDA is a non-GAAP financial measure. We define Adjusted EBITDA as EBITDA adjusted for the impact of various significant or unusual transactions. We believe that Adjusted EBITDA is a useful metric to evaluate our operating performance and that it may increase comparability with companies in the cannabis industry by adjusting for variability resulting from differences in capital structures, resource allocations and investments, the impact of fair value adjustments on biological assets and inventory and financial statements, which may be volatile and fluctuate significantly from period to period. However, other companies may also calculate these measures differently, which would limit their usefulness as a comparative measure. |
|
4 For purposes of calculating 2024 Adjusted EBITDA margin, we excluded revenue associated with the terminated Vireo consulting agreement from the denominator, consistent with the exclusion of related (income) or expense from Adjusted EBITDA. As a result, the 2024 Adjusted EBITDA margin presented does not correspond directly to the revenue amounts shown in the table. On this basis, 2024 Adjusted EBITDA margin was approximately 19.4%. |
|
5
Cash and cash equivalents are presented as of |
Selected Preliminary Annual Revenue by Segment
(Unaudited) (US$ in millions)
|
Segment |
Revenue 2025 |
Revenue 2024 |
YoY Δ |
|
|
|
|
(8 %) |
|
|
|
|
(22 %) |
|
|
|
|
n.m. |
|
Corporate / Other ** |
|
|
n.m. |
|
*
|
Conference Call and Webcast Information
To further enhance investor disclosure, the Company will also post an updated Company Overview presentation to its website in advance of the call.
Conference Call Details
|
Date: |
|
|
Time: |
|
|
Webcast: |
|
|
Dial-in: |
1-800-836-8184 (Toll-Free in |
A telephone replay of the conference call will be available until
The webcast will be archived on
About
Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) (Unaudited)
For the years ended
(US$ in millions)
|
|
|
|
|
|
|
|
|
|
|
|
|
2025 |
|
|
2024 |
|
||
|
|
|
|
|
|
(Note 3.1) |
|
||
|
|
|
$ |
|
|
$ |
|
||
|
Revenue |
|
|
|
|
|
|
|
|
|
Product sales |
|
|
32,427,936 |
|
|
|
25,364,193 |
|
|
Service revenue |
|
|
- |
|
|
|
1,258,131 |
|
|
Total revenue |
|
|
32,427,936 |
|
|
|
26,622,324 |
|
|
Cost of goods sold |
|
|
|
|
|
|
|
|
|
Cost of finished cannabis inventory sold |
|
|
(18,281,254) |
|
|
|
(13,172,677) |
|
|
Costs of service revenue |
|
|
- |
|
|
|
(206,669) |
|
|
Total cost of goods sold |
|
|
(18,281,254) |
|
|
|
(13,379,346) |
|
|
Gross profit |
|
|
14,146,682 |
|
|
|
13,242,978 |
|
|
Operating expenses |
|
|
|
|
|
|
|
|
|
Amortization (Notes 10, 11) |
|
|
702,258 |
|
|
|
993,379 |
|
|
General and administrative |
|
|
11,643,917 |
|
|
|
10,580,794 |
|
|
Share-based compensation (Notes 19, 20) |
|
|
2,393,994 |
|
|
|
1,608,823 |
|
|
Total operating expenses |
|
|
14,740,169 |
|
|
|
13,182,996 |
|
|
Income (loss) from operations |
|
|
(593,487) |
|
|
|
59,982 |
|
|
Other income (expense) |
|
|
|
|
|
|
|
|
|
Interest expense (Note 13,15) |
|
|
(150,331) |
|
|
|
(77,513) |
|
|
Accretion expense (Notes 13,14,15) |
|
|
(1,234,423) |
|
|
|
(1,836,440) |
|
|
Other income (Note 11) |
|
|
932,730 |
|
|
|
1,090,649 |
|
|
Interest income (Note 9) |
|
|
179,731 |
|
|
|
350,656 |
|
|
Unrealized gain (loss) on derivative liability (Note 16) |
|
|
44,917 |
|
|
|
(7,754,402) |
|
|
Realized gain (loss) on derivative liability (Note 16) |
|
|
5,859,744 |
|
|
|
(5,049,209) |
|
|
Unrealized gain on warrant asset (Note 7) |
|
|
247,477 |
|
|
|
3,094,413 |
|
|
Realized loss on warrant liability (Note 17) |
|
|
- |
|
|
|
(1,741,710) |
|
|
Loss on equity investment in associate (Note 8) |
|
|
(452,962) |
|
|
|
(251,230) |
|
|
Total other income (expense), net |
|
|
5,426,883 |
|
|
|
(12,174,786) |
|
|
Income (loss) before income tax expense |
|
|
4,833,396 |
|
|
|
(12,114,804) |
|
|
Income tax expense (Note 22) |
|
|
(1,603,439) |
|
|
|
(3,864,547) |
|
|
Net income (loss) |
|
|
3,229,957 |
|
|
|
(15,979,351) |
|
|
Other comprehensive income (loss) |
|
|
|
|
|
|
|
|
|
Currency translation adjustment |
|
|
4,024 |
|
|
|
(17,861) |
|
|
Total comprehensive income (loss) |
|
|
3,233,981 |
|
|
|
(15,997,212) |
|
|
|
|
|
|
|
|
|
|
|
|
Basic and diluted income (loss) per share (Note 21) |
|
|
0.01 |
|
|
|
(0.08) |
|
|
Basic and diluted weighted average number of subordinate voting common shares outstanding |
|
|
243,446,152 |
|
|
|
209,441,723 |
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) for the period attributable to: |
|
|
|
|
|
|
|
|
|
Shareholders |
|
|
1,729,805 |
|
|
|
(16,006,379) |
|
|
Non-controlling interest |
|
|
1,500,152 |
|
|
|
27,028 |
|
|
Net income (loss) |
|
|
3,229,957 |
|
|
|
(15,979,351) |
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income (loss) for the period attributable to: |
|
|
|
|
|
|
|
|
|
Shareholders |
|
|
1,733,829 |
|
|
|
(16,024,240) |
|
|
Non-controlling interest |
|
|
1,500,152 |
|
|
|
27,028 |
|
|
Total comprehensive income (loss) |
|
|
3,233,981 |
|
|
|
(15,997,212) |
|
Consolidated Balance Sheets (Unaudited)
As of
(US$ in millions)
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
December 31, |
|
||
|
|
|
|
|
|
(Note 3,1) |
|
||
|
|
|
$ |
|
|
$ |
|
||
|
ASSETS |
|
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
|
11,371,834 |
|
|
|
4,917,708 |
|
|
Accounts receivable, net (Note 5) |
|
|
2,908,270 |
|
|
|
1,557,125 |
|
|
Inventory (Note 6) |
|
|
7,081,295 |
|
|
|
5,941,551 |
|
|
Prepaid expenses |
|
|
563,912 |
|
|
|
699,362 |
|
|
Current portion of notes receivable (Note 9) |
|
|
253,403 |
|
|
|
- |
|
|
Total current assets |
|
|
22,178,714 |
|
|
|
13,115,746 |
|
|
Other long-term assets |
|
|
300,000 |
|
|
|
200,000 |
|
|
Warrants asset (Note 7) |
|
|
5,103,272 |
|
|
|
4,855,795 |
|
|
Other Investments (Note 8) |
|
|
1,358,860 |
|
|
|
575,967 |
|
|
Notes receivable (Note 9) |
|
|
1,683,757 |
|
|
|
1,538,011 |
|
|
Lease receivable (Note 11) |
|
|
94,022 |
|
|
|
- |
|
|
Property and equipment, net (Note 10) |
|
|
14,055,552 |
|
|
|
14,044,233 |
|
|
Right of use assets (Note 11) |
|
|
13,414,406 |
|
|
|
7,591,048 |
|
|
Deferred tax asset (Note 22) |
|
|
1,522,760 |
|
|
|
692,105 |
|
|
Intangible assets (Note 12) |
|
|
3,025,193 |
|
|
|
3,025,193 |
|
|
TOTAL ASSETS |
|
|
62,736,536 |
|
|
|
45,638,098 |
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES |
|
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
|
Accounts payable and accrued liabilities |
|
|
1,262,519 |
|
|
|
2,690,907 |
|
|
Current portion of operating lease liabilities (Note 11) |
|
|
844,421 |
|
|
|
1,047,763 |
|
|
Current portion of finance lease liabilities (Note 11) |
|
|
152,705 |
|
|
|
- |
|
|
Current portion of long-term debt (Note 13) |
|
|
2,576,228 |
|
|
|
227,680 |
|
|
Convertible debentures (Note 15) |
|
|
- |
|
|
|
663,736 |
|
|
Current portion of consideration payable on business acquisitions (Note 14) |
|
|
455,844 |
|
|
|
536,881 |
|
|
Derivative liability (Note 16) |
|
|
137,041 |
|
|
|
12,504,180 |
|
|
Income tax payable (Note 22) |
|
|
158,848 |
|
|
|
1,916,726 |
|
|
Total current liabilities |
|
|
5,724,776 |
|
|
|
19,587,873 |
|
|
Operating lease liabilities, net of current portion (Note 11) |
|
|
13,010,805 |
|
|
|
6,699,808 |
|
|
Finance lease liabilities, net of current portion (Note 11) |
|
|
67,782 |
|
|
|
- |
|
|
Long-term debt, net of discounts and current portion (Note 13) |
|
|
10,019,301 |
|
|
|
2,074,110 |
|
|
Consideration payable on business acquisitions, net of discounts and current portion (Note 14) |
|
|
1,611,637 |
|
|
|
1,693,540 |
|
|
Other non-current liabilities (Note 22) |
|
|
8,383,888 |
|
|
|
5,007,148 |
|
|
TOTAL LIABILITIES |
|
|
38,818,189 |
|
|
|
35,062,479 |
|
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies (Note 28) |
|
|
|
|
|
|
|
|
|
Subsequent events (Note 29) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SHAREHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
|
Subordinate voting common shares, convertible into multiple voting common shares, no par value; unlimited shares authorized; 249,738,980 and 222,446,113 shares issued and outstanding as at |
|
|
62,589,075 |
|
|
|
52,365,328 |
|
|
Multiple voting common shares, no par value; unlimited shares authorized; nil and nil shares issued and outstanding as at |
|
|
- |
|
|
|
- |
|
|
Accumulated other comprehensive loss |
|
|
(121,906) |
|
|
|
(125,930) |
|
|
Accumulated deficit |
|
|
(41,563,955) |
|
|
|
(43,293,760) |
|
|
Equity attributable to |
|
|
20,903,214 |
|
|
|
8,945,638 |
|
|
Non-controlling interests (Note 27) |
|
|
3,015,133 |
|
|
|
1,629,981 |
|
|
TOTAL SHAREHOLDERS' EQUITY |
|
|
23,918,347 |
|
|
|
10,575,619 |
|
|
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY |
|
|
62,736,536 |
|
|
|
45,638,098 |
|
Consolidated Statements of Cash Flow (Unaudited)
For the Years Ended
(US$ in millions)
|
|
|
|
|
|
|
|
|
|
|
|
|
2025 |
|
|
2024 |
|
||
|
|
|
|
|
|
Note 3.1 |
|
||
|
|
|
$ |
|
|
$ |
|
||
|
Operating activities |
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
|
3,229,957 |
|
|
|
(15,979,351) |
|
|
Adjustments for non-cash items in net income (loss): |
|
|
|
|
|
|
|
|
|
Depreciation of property and equipment |
|
|
702,258 |
|
|
|
993,379 |
|
|
Depreciation of property and equipment included in costs of finished cannabis inventory sold |
|
|
2,140,694 |
|
|
|
436,047 |
|
|
Lease costs included in costs of finished cannabis inventory sold |
|
|
549,964 |
|
|
|
328,957 |
|
|
Share-based compensation |
|
|
2,393,994 |
|
|
|
1,608,823 |
|
|
Interest expense |
|
|
150,331 |
|
|
|
- |
|
|
Accretion expense |
|
|
1,234,423 |
|
|
|
1,836,440 |
|
|
Other income |
|
|
(165,743) |
|
|
|
- |
|
|
Interest income |
|
|
(149,149) |
|
|
|
- |
|
|
Unrealized (gain) loss on derivative liability |
|
|
(44,917) |
|
|
|
7,754,402 |
|
|
Realized (gain) loss on derivative liability |
|
|
(5,859,744) |
|
|
|
5,049,209 |
|
|
Unrealized gain on warrant asset |
|
|
(247,477) |
|
|
|
(3,094,413) |
|
|
Realized loss on warrant liability |
|
|
- |
|
|
|
1,741,710 |
|
|
Loss on equity investment in associate |
|
|
452,962 |
|
|
|
251,230 |
|
|
Loss on disposal of property and equipment |
|
|
- |
|
|
|
(50,057) |
|
|
Deferred income taxes |
|
|
(830,655) |
|
|
|
(112,198) |
|
|
|
|
|
3,556,898 |
|
|
|
764,178 |
|
|
Changes in non-cash working capital (Note 23) |
|
|
12,897 |
|
|
|
1,850,802 |
|
|
Net cash provided by operating activities |
|
|
3,569,795 |
|
|
|
2,614,980 |
|
|
|
|
|
|
|
|
|
|
|
|
Investing activities |
|
|
|
|
|
|
|
|
|
Purchase of property and equipment |
|
|
(4,659,006) |
|
|
|
(4,082,154) |
|
|
Acquisition of |
|
|
(437,375) |
|
|
|
- |
|
|
Acquisition of |
|
|
(173,157) |
|
|
|
(271,438) |
|
|
Dividend issued from |
|
|
(115,000) |
|
|
|
(530,000) |
|
|
Advance of notes receivable |
|
|
(250,000) |
|
|
|
(1,547,678) |
|
|
Repayment of notes receivable |
|
|
- |
|
|
|
266,417 |
|
|
Investment in |
|
|
- |
|
|
|
(1,980,000) |
|
|
Cash acquired on investment in |
|
|
- |
|
|
|
2,815 |
|
|
Advance on purchase of remaining |
|
|
(1,235,855) |
|
|
|
(827,197) |
|
|
Net cash used in investing activities |
|
|
(6,870,393) |
|
|
|
(8,969,235) |
|
|
|
|
|
|
|
|
|
|
|
|
Financing activities |
|
|
|
|
|
|
|
|
|
Proceeds from exercise of stock options |
|
|
406,944 |
|
|
|
359,958 |
|
|
Proceeds from exercise of warrants |
|
|
- |
|
|
|
4,609,577 |
|
|
Proceeds from long-term debt |
|
|
12,630,345 |
|
|
|
450,000 |
|
|
Debt issuance costs |
|
|
(739,313) |
|
|
|
(126,914) |
|
|
Repayment of long-term debt |
|
|
(2,467,521) |
|
|
|
(1,141,437) |
|
|
Payment of interest on convertible debentures |
|
|
(79,755) |
|
|
|
(453,439) |
|
|
Proceeds from sale of units of subsidiary |
|
|
- |
|
|
|
787,500 |
|
|
Net cash provided by financing activities |
|
|
9,750,700 |
|
|
|
4,485,245 |
|
|
|
|
|
|
|
|
|
|
|
|
Effect of foreign exchange on cash and cash equivalents |
|
|
4,024 |
|
|
|
(17,861) |
|
|
|
|
|
|
|
|
|
|
|
|
Change in cash and cash equivalents |
|
|
6,454,126 |
|
|
|
(1,886,871) |
|
|
Cash and cash equivalents, beginning of year |
|
|
4,917,708 |
|
|
|
6,804,579 |
|
|
Cash and cash equivalents, ending of year |
|
|
11,371,834 |
|
|
|
4,917,708 |
|
Note: Selected financial information is summarized from the Company's preliminary, unaudited consolidated financial information for the year ended
Adjusted EBITDA Reconciliation Table (Preliminary, Unaudited)
(US$ in millions)
|
Years ended December 31: |
|
2025 |
|
|
2024 |
|
||
|
|
|
$ |
|
|
$ |
|
||
|
Adjusted EBITDA Reconciliation |
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
|
3,229,957 |
|
|
|
(15,979,351) |
|
|
Add back amortization of property and equipment included in cost of sales |
|
|
2,690,658 |
|
|
|
765,004 |
|
|
Add back interest and interest accretion expense |
|
|
1,384,754 |
|
|
|
1,913,953 |
|
|
Add back amortization of property and equipment |
|
|
702,258 |
|
|
|
993,379 |
|
|
Add back loss on equity investment in associate |
|
|
452,962 |
|
|
|
251,230 |
|
|
Add back income tax expense |
|
|
1,603,439 |
|
|
|
3,864,547 |
|
|
Deduct unrealized gain / add back unrealized loss on derivative liability |
|
|
(5,904,661) |
|
|
|
14,545,321 |
|
|
Deduct interest expense and other income (expense) |
|
|
(1,112,461) |
|
|
|
(1,441,305) |
|
|
Deduct unrealized gain on warrants asset |
|
|
(247,477) |
|
|
|
(3,094,413) |
|
|
EBITDA |
|
|
2,799,429 |
|
|
|
1,818,365 |
|
|
Compliance costs1 |
|
|
|
|
|
|
|
|
|
Add back share-based compensation |
|
|
2,393,994 |
|
|
|
1,608,823 |
|
|
Add back costs associated with acquisition of Golden Harvests1 |
|
|
120,000 |
|
|
|
603,000 |
|
|
Add back pre-revenue new market startup costs2 |
|
|
72,217 |
|
|
|
783,720 |
|
|
Deduct non-recurring services revenue3 |
|
|
- |
|
|
|
(1,051,462) |
|
|
Adjusted EBITDA |
|
|
5,385,640 |
|
|
|
3,762,446 |
|
|
1
Costs associated with the Company's acquisition of the |
|
2
During the years ended December 31, 2025 and 2024, we incurred |
|
3
On |
Preliminary Segmented Adjusted EBITDA (Unaudited) – Twelve months ended
(US$ in millions)
|
|
|
|
|
|
|
|
|
|
|
|
Corporate |
|
|
Consolidated |
|
|
||||||
|
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
$ |
|
|
||||||
|
Revenue |
|
|
11,059,993 |
|
|
|
10,032,271 |
|
|
|
11,335,672 |
|
|
|
- |
|
|
|
32,427,936 |
|
||
|
Costs of revenue |
|
|
(7,904,485) |
|
|
|
(5,104,917) |
|
|
|
(5,271,852) |
|
|
|
- |
|
|
|
(18,281,254) |
|
||
|
Gross profit |
|
|
3,155,508 |
|
|
|
4,927,354 |
|
|
|
6,063,820 |
|
|
|
- |
|
|
|
14,146,682 |
|
||
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
General and administration |
|
|
2,570,592 |
|
|
|
2,389,021 |
|
|
|
1,320,605 |
|
|
|
5,363,699 |
|
|
|
11,643,917 |
|
||
|
Depreciation and amortization |
|
|
213,066 |
|
|
|
185,361 |
|
|
|
243,760 |
|
|
|
60,071 |
|
|
|
702,258 |
|
||
|
Share-based compensation |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
2,393,994 |
|
|
|
2,393,994 |
|
||
|
Other income and expense: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
Interest and accretion |
|
|
(10,004) |
|
|
|
(14,126) |
|
|
|
(129,917) |
|
|
|
(1,230,707) |
|
|
|
(1,384,754) |
|
||
|
Interest and other income (expense) |
|
|
118,685 |
|
|
|
(24,427) |
|
|
|
259,747 |
|
|
|
758,456 |
|
|
|
1,112,461 |
|
||
|
Unrealized loss on derivative liability |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
44,917 |
|
|
|
44,917 |
|
||
|
Realized loss on derivative liability |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
5,859,744 |
|
|
|
5,859,744 |
|
||
|
Unrealized loss on warrants asset |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
247,477 |
|
|
|
247,477 |
|
||
|
Loss on equity method investment in associate |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(452,962) |
|
|
|
(452,962) |
|
||
|
Net income (loss) before income tax |
|
|
480,531 |
|
|
|
2,314,419 |
|
|
|
4,629,286 |
|
|
|
(2,590,840) |
|
|
|
4,833,396 |
|
||
|
Income tax |
|
|
- |
|
|
|
104,288 |
|
|
|
(118,780) |
|
|
|
(1,588,947) |
|
|
|
(1,603,439) |
|
||
|
Net income (loss) after income tax |
|
|
480,531 |
|
|
|
2,418,707 |
|
|
|
4,510,506 |
|
|
|
(4,179,787) |
|
|
|
3,229,957 |
|
||
|
Amortization of property and equipment included in cost of sales |
|
|
573,545 |
|
|
|
842,566 |
|
|
|
1,274,547 |
|
|
|
- |
|
|
|
2,690,658 |
|
||
|
Interest and accretion |
|
|
10,004 |
|
|
|
14,126 |
|
|
|
129,917 |
|
|
|
1,230,707 |
|
|
|
1,384,754 |
|
||
|
Amortization of property and equipment |
|
|
213,066 |
|
|
|
185,361 |
|
|
|
243,760 |
|
|
|
60,071 |
|
|
|
702,258 |
|
||
|
Loss on equity method investment in associate |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
452,962 |
|
|
|
452,962 |
|
||
|
Income tax |
|
|
- |
|
|
|
(104,288) |
|
|
|
118,780 |
|
|
|
1,588,947 |
|
|
|
1,603,439 |
|
||
|
Change in fair value of derivative liability |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(5,904,661) |
|
|
|
(5,904,661) |
|
||
|
Interest and other income (expense) |
|
|
(118,685) |
|
|
|
24,427 |
|
|
|
(259,747) |
|
|
|
(758,456) |
|
|
|
(1,112,461) |
|
||
|
Unrealized loss on warrant asset |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(247,477) |
|
|
|
(247,477) |
|
||
|
EBITDA before one-time adjustments |
|
|
1,158,461 |
|
|
|
3,380,899 |
|
|
|
6,017,762 |
|
|
|
(7,757,693) |
|
|
|
2,799,429 |
|
||
|
Add back to EBITDA: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||
|
Share-based compensation |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
2,393,994 |
|
|
|
2,393,994 |
|
||
|
Costs associated with acquisition of Golden Harvests |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
120,000 |
|
|
|
120,000 |
|
||
|
Add back pre-revenue new market startup costs2 |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
72,217 |
|
|
|
72,217 |
|
||
|
Adjusted EBITDA |
|
|
1,158,461 |
|
|
|
3,380,899 |
|
|
|
6,017,762 |
|
|
|
(5,171,482) |
|
|
|
5,385,640 |
|
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preliminary Quarterly Adjusted EBITDA (Unaudited) – 2025
(US$ in millions)
|
|
|
Q1 2025 |
|
Q2 2025 |
|
Q3 2025 |
|
Q4 2025 |
|
|
|
$ |
|
$ |
|
$ |
|
$ |
|
Revenue |
|
7,150,183 |
|
8,009,987 |
|
8,514,268 |
|
8,753,498 |
|
Total cost of goods sold |
|
(3,786,436) |
|
(4,455,502) |
|
(4,855,244) |
|
(5,184,072) |
|
Gross profit |
|
3,363,747 |
|
3,554,485 |
|
3,659,024 |
|
3,569,426 |
|
Operating expenses |
|
|
|
|
|
|
|
|
|
General and administration |
|
2,532,254 |
|
2,678,371 |
|
2,964,471 |
|
3,468,821 |
|
Depreciation and amortization |
|
91,463 |
|
94,407 |
|
97,174 |
|
419,214 |
|
Share based compensation |
|
1,435,910 |
|
336,825 |
|
314,951 |
|
306,308 |
|
Other income and expense: |
|
|
|
|
|
|
|
|
|
Interest and accretion |
|
(258,171) |
|
(432,553) |
|
(410,925) |
|
(283,105) |
|
Interest and other income (expense) |
|
757,067 |
|
16,821 |
|
248,386 |
|
90,187 |
|
Unrealized loss on derivative liability |
|
2,835,988 |
|
(2,808,334) |
|
24,242 |
|
(6,979) |
|
Realized gain on derivative liability |
|
- |
|
5,813,507 |
|
- |
|
46,237 |
|
Unrealized gain (loss) on warrants asset |
|
(1,172,492) |
|
(168,162) |
|
2,162,087 |
|
(573,956) |
|
Loss on equity method investment in associate |
|
(153,734) |
|
(114,686) |
|
(75,733) |
|
(108,809) |
|
Net income (loss) before tax |
|
1,312,778 |
|
2,751,475 |
|
2,230,485 |
|
(1,461,342) |
|
Tax |
|
(252,985) |
|
(541,711) |
|
(133,055) |
|
(675,688) |
|
Net income (loss) |
|
1,059,793 |
|
2,209,764 |
|
2,097,430 |
|
(2,137,030) |
|
Amortization included in cost of sales |
|
434,202 |
|
658,232 |
|
895,472 |
|
702,751 |
|
Amortization of property and equipment |
|
91,463 |
|
94,407 |
|
97,174 |
|
419,214 |
|
Change in fair value of derivative liability |
|
(2,835,988) |
|
(3,005,173) |
|
(24,242) |
|
(39,258) |
|
Unrealized warrants asset |
|
1,172,492 |
|
168,162 |
|
(2,162,087) |
|
573,956 |
|
Loss on equity method investment in associate |
|
153,734 |
|
114,686 |
|
75,733 |
|
108,809 |
|
Interest and other income (expense) |
|
(757,067) |
|
(16,821) |
|
(248,386) |
|
(90,187) |
|
Interest and accretion |
|
258,171 |
|
432,553 |
|
410,925 |
|
283,105 |
|
Income tax |
|
252,985 |
|
541,711 |
|
133,055 |
|
675,688 |
|
EBITDA before one-time adjustments |
|
(170,215) |
|
1,197,521 |
|
1,275,074 |
|
497,048 |
|
Add back share-based compensation |
|
1,435,910 |
|
336,825 |
|
314,951 |
|
306,308 |
|
Costs related to acquisition of Golden Harvests |
|
- |
|
60,000 |
|
- |
|
60,000 |
|
Q4 |
|
(79,000) |
|
(79,000) |
|
(79,000) |
|
237,000 |
|
Add back pre-revenue new market startup costs |
|
- |
|
- |
|
- |
|
72,217 |
|
Adjusted EBITDA |
|
1,186,695 |
|
1,515,346 |
|
1,511,025 |
|
1,172,573 |
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release contains "forward looking information" and "forward-looking statements" within the meaning of applicable securities laws, including, without limitation, statements regarding: the Company's financial guidance and long-term targets; anticipated timing, capacity, ramp and revenue contributions in
Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Although the Company believes that the expectations reflected in these statements are reasonable, forward-looking statements are based on management's current expectations, estimates, assumptions and projections as of the date of this release, including, without limitation, assumptions regarding market conditions, wholesale pricing, demand, construction timelines, regulatory approvals, capital availability, operating performance, and the timing of new market launches and expansion projects. Although the Company believes these assumptions are reasonable, forward-looking statements are inherently subject to risks and uncertainties, and undue reliance should not be placed on such statements.
Actual results may differ materially from those expressed or implied by forward-looking statements as a result of a number of known and unknown risks and uncertainties, including, without limitation: changes in general economic, business and political conditions; access to debt or equity capital on acceptable terms; adverse changes in the public perception of cannabis; decreases in prevailing prices for cannabis and cannabis products in the markets in which the Company operates; regulatory developments and the timing or availability of required approvals; the pace and cost of construction, commissioning and ramp activities; and the other risks described in the Company's public disclosure documents filed on SEDAR+ and www.sec.gov.
The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Readers are cautioned that future-oriented financial information and financial outlooks contained in this release are provided for the purpose of describing management's current expectations and may not be appropriate for other purposes. The Company is indirectly involved in the manufacture, possession, use, sale and distribution of cannabis in the recreational cannabis marketplace in
Non-GAAP Financial Measures
This press release contains certain non-GAAP financial measures. These measures are presented as supplemental information and should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliations of these non-GAAP measures to the most directly comparable GAAP measures are included in the financial schedules accompanying this release. Forward-looking non-GAAP guidance is provided on the basis described under "Guidance and Long-Term Growth Objectives."
SOURCE